Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.

被引：0
|
作者：
Lu, Nian
Jiang, Yao-Fei
Xia, Weixiong
Huang, Ying
Xie, Chuan-Miao
Xu, Cheng
Ye, Yan-Fang
Liu, Guo-Ying
Bei, Wei-Xin
Ke, Liang-Ru
Li, Wang-Zhong
Wang, Xin
Xie, Changqing
Liang, Hu
Xiang Yanqun
机构：
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc,Guangdong Key Lab Nasopharyngeal Carcino, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Clin Res Design Div, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[8] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[9] Sun Yat Sen Univ, Dept Med Imaging, Ctr Canc, Guangzhou, Peoples R China
[10] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg & Oncol,Guangzhou Inst Resp Hlth, Natl Clin Res Ctr Resp Dis,State Key Lab Resp Dis, Guangzhou, Peoples R China
[11] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, OH USA
[12] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6031
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of perioperative sintilimab plus platinum based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trial
    Yu, Xiangyang
    Huang, Chujian
    Du, Longde
    Wang, Chunguang
    Yang, Yikun
    Yu, Xin
    Lin, Shengcheng
    Yang, Chenglin
    Zhao, Hongbo
    Cai, Songhua
    Wang, Zhe
    Wang, Lixu
    Guo, Xiaotong
    Zhang, Baihua
    Yu, Zhentao
    He, Jie
    Ma, Kai
    ECLINICALMEDICINE, 2025, 79
  • [32] Efficacy and safety of vitamin K with sorafenib combination treatment against hepatocellular carcinoma: Open-label, randomized phase II study.
    Haruna, Yoshimichi
    Inoue, Atsuo
    Kawamoto, Seiichi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Chemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial
    Chen, M.
    You, R.
    You-Ping, L.
    Huang, P-Y.
    Zou, X.
    Shen, G-P.
    Zhang, H-D.
    ANNALS OF ONCOLOGY, 2019, 30 : 449 - 449
  • [34] Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study
    Zhang, Ge
    Gong, Shuai
    Pang, Lina
    Hou, Lixia
    He, Wei
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
    Tang, Lin-Quan
    Li, Xiao-Yun
    Li, Zhi-Ming
    Liu, Zhi-Gang
    Lin, Miao-Zhen
    Zhou, Huan
    Yu, Qi-Wen
    Zhou, Jian
    Zhao, Chong
    Chen, Ze-Bin
    Wang, Xi-Cheng
    Peng, Jia-Yu
    Chen, Qiu-Yan
    Fang, Wen-Feng
    Yang, Yun-Peng
    Zhang, Bei
    Xia, Liang-Ping
    Hu, Pi-Li
    Hu, Wei-Han
    Li, Yi-Jie
    Mai, Hai-Qiang
    Cai, Xiu-Yu
    BMC MEDICINE, 2023, 21 (01)
  • [36] The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
    Lin-Quan Tang
    Xiao-Yun Li
    Zhi-Ming Li
    Zhi-Gang Liu
    Miao-Zhen Lin
    Huan Zhou
    Qi-Wen Yu
    Jian Zhou
    Chong Zhao
    Ze-Bin Chen
    Xi-Cheng Wang
    Jia-Yu Peng
    Qiu-Yan Chen
    Wen-Feng Fang
    Yun-Peng Yang
    Bei Zhang
    Liang-Ping Xia
    Pi-Li Hu
    Wei-Han Hu
    Yi-Jie Li
    Hai-Qiang Mai
    Xiu-Yu Cai
    BMC Medicine, 21
  • [37] Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
    Jiang, Haiping
    Zheng, Yulong
    Qian, Jiong
    Mao, Chenyu
    Xu, Xin
    Li, Ning
    Xiao, Cheng
    Wang, Huan
    Teng, Lisong
    Zhou, Hui
    Wang, Shuyan
    Zhu, Donglei
    Sun, Tao
    Yu, Yingying
    Guo, Wenying
    Xu, Nong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (03) : 857 - 868
  • [38] Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
    Faivre, Sandrine
    Raymond, Eric
    Boucher, Eveline
    Douillard, Jean
    Lim, Ho Y.
    Kim, Jun S.
    Zappa, Magaly
    Lanzalone, Silvana
    Lin, Xun
    DePrimo, Samuel
    Harmon, Charles
    Ruiz-Garcia, Ana
    Lechuga, Maria J.
    Cheng, Ann Lii
    LANCET ONCOLOGY, 2009, 10 (08): : 794 - 800
  • [39] Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
    Haiping Jiang
    Yulong Zheng
    Jiong Qian
    Chenyu Mao
    Xin Xu
    Ning Li
    Cheng Xiao
    Huan Wang
    Lisong Teng
    Hui Zhou
    Shuyan Wang
    Donglei Zhu
    Tao Sun
    Yingying Yu
    Wenying Guo
    Nong Xu
    Cancer Immunology, Immunotherapy, 2021, 70 : 857 - 868
  • [40] The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.
    Yang, Xin-Rong
    Cheng, Jian-Wen
    Wu, Suiyi
    Hu, Bo
    Qiu, Shuang-Jian
    Sun, Hui-Chuan
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345